Beta Bionics, based in the US, has announced the first patients have begun home use of dasiglucagon – a stable glucagon analogue – in a clinical trial of the company’s iLet bionic pancreas system for people with Type 1 diabetes.
The iLet device features an autonomous, dual-chamber infusion pump that is powered by dosing algorithms. Using machine learning and data from a continuous glucose monitor, the algorithms calculate and dose insulin and/or glucagon as needed. The iLet can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas (insulin and glucagon), and the trial will compare the operational performance in its insulin-only configuration to that of its bihormonal configuration using dasiglucagon.
